Andere talen Clarity Pharmaceuticals Ltd

Aandelen

CU6

AU0000165375

Beurs gesloten - Australian S.E. Andere beurzen 08:10:14 09-05-2024			Variatie 5 dagen	Verschil t.o.v. 1 jan (%)
3,96 ^AUD	+1,02%		+31,56%	+108,42%

24/04	Clarity Pharmaceuticals rondt kleinschalig aanbod van AU$10,8 miljoen af	MT
04/04	Clarity Pharmaceuticals ondertekent leveringsovereenkomst met NorthStar Medical Radioisotopes	MT

Andere talen

Krijg toegang tot al het nieuws over alle bedrijven: mis nooit meer een winstgevende beleggingskans!

Gratis inschrijven

Clarity Pharmaceuticals Completes AU$10.8 Million Retail Entitlement Offer	24/04
Clarity Pharmaceuticals Signs Supply Agreement with NorthStar Medical Radioisotopes	04/04
Clarity Pharmaceuticals Concludes Placement and Institutional Entitlement Offer; Shares Decline 4%	28/03
Clarity Pharmaceuticals to Raise AU$121 Million via Fully Underwritten Equity Raising	26/03
Clarity Pharmaceuticals' SECuRE Trial Treats First Participant in Last Dose Escalation Cohort; Shares Down 5%	22/03
Clarity Pharmaceuticals Ltd(ASX:CU6) added to S&P/ASX All Ordinaries Index	18/03
Clarity Pharmaceuticals Announces the Successful Completion of Cohort 3 and Advancement to Cohort 4, the First Multi-Dose Cohort in the SECuRE Trial	15/03
Clarity Pharmaceuticals Prostate Cancer Trial Advances	15/03
Clarity Pharmaceuticals Ltd. Announces Additional COBRA Results: SAR-bisPSMA Detects Lesions in the 2-Millimetre Range	08/03
Clarity Pharmaceuticals Ltd Reports Earnings Results for the Half Year Ended December 31, 2023	29/02
Clarity Pharmaceuticals Reports Safety, Effectivity of Prostate Cancer Lesion Detection System in US Trial	15/02
Clarity Pharmaceuticals Ltd Announces Resignation of Non-Executive Directors	15/01
Clarity Pharmaceuticals Announces First Patient Dosed in Registrational Phase III Prostate Cancer Trial with Cu-64 SAR-BispsMA	22/12
Clarity Pharmaceuticals Doses First Patient in Phase Three Prostate Cancer Trial	22/12
Clarity Pharmaceuticals Closes Recruitment for Phase 2 Trial in Neuroendocrine Tumors	20/12
Clarity Pharmaceuticals Ltd Commences Registrational Phase III Clarify Trial in Prostate Cancer	30/11
Clarity Pharmaceuticals Ltd. Announces First Patient with Metastatic Prostate Cancer to Receive 2 Doses of Cu-67 SAR-bisPSMA Achieves Undetectable PSA Level	30/11
Clarity's theranostic prostate cancer trial progresses at the highest dose level cohort	30/11
Clarity Pharmaceuticals Announces Successful Completion of First Stage of Cohort 3 of Phase I/IIa Theranostic Trial, SECuRE	29/11
Clarity Pharmaceuticals Announces Recruitment Target Achieves for Phase II Sar-Bombesin Prostate Cancer Trial	07/11

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen Clarity Pharmaceuticals Ltd

Aandelen

CU6

AU0000165375

Andere talen

Filters